When we wrote the CAR-T price-gap breakdown, the category’s China list prices ran ¥999,000–1.29 million (roughly US$140,000–180,000) against US list prices of US$373,000–525,000, and the question was how far and how fast the Chinese floor could fall. June 2026 delivered the most interesting datapoint yet: CARsgen’s satri-cel — the world’s first regulatory approval of a CAR-T for a solid tumour, for previously treated advanced gastric cancer — launched at ¥990,000 (about US$138,000) per dose.
A new floor, set deliberately
¥990,000 undercuts the cheapest blood-cancer CAR-T on the Chinese market by ¥9,000 — not a dramatic cut in isolation, but a marker: the first new CAR-T to launch in China since our breakdown priced below the category’s existing floor. Coverage of the launch notes the price position against domestic rivals; in a September interview, CARsgen founder Li Zonghai attributed the number to in-house manufacturing technology and self-developed production — the same localisation logic that has driven every step down so far. His framing was that getting CAR-T into solid tumours is “only the first step”.
The direction was already signalled. As we documented in the original breakdown, one domestic manufacturer had signalled a launch price of ¥230,000–250,000 for its next product, crediting localised non-customised production, and by mid-2026 Chinese media counted eight marketed CAR-T products — more manufacturers than any other country. What makes satri-cel’s ¥990,000 interesting is that it is the first test of whether that scale logic transfers from blood cancers, where manufacturing is now routine, to solid tumours, where it has never been done at commercial scale anywhere. The floor moved less than the bulls expected; the category it anchors moved further than any competitor’s.
The harder question: what does ¥990,000 buy?
The price landed in the middle of an uncomfortable debate. Media coverage of satri-cel’s pivotal trial reported a median overall-survival benefit of roughly two additional months against physician’s-choice treatment — which is why the ¥990,000 figure became a national talking point rather than a routine pricing announcement. Two months of median survival for the price of a house is the calculation that oncologists, patients and payers are now arguing about in public.
The payer side is moving too. Industry coverage of the 2026 national reimbursement negotiation season lists CAR-T among the contested categories — million-yuan cell therapies pushing against the state drug list’s budget math — while the commercial-insurance route we documented (five CAR-T products negotiated into the innovative-drug catalogue, with out-of-pocket around ¥40,000 for covered domestic policyholders) remains the other track. Satri-cel’s eligibility for either is, as of this month, an open question being watched closely.
What it does not mean — unchanged from our last breakdown
For a foreign patient, none of this is a flight booking, and the caveats have not moved. CAR-T is prescribed for specific cancers under specific conditions; eligibility and follow-up belong with oncologists. Foreign self-pay patients negotiate with hospitals’ international departments at close to list prices — the catalogue prices are for domestic policies. Episode-of-care costs run well past the drug itself in both countries. The full sourced landscape stays on our advanced oncology and cell therapy page, and the general method for reading these numbers — one price is not a system — is the checklist we apply to every claim.
What the satri-cel launch actually documents is direction: a first-in-class therapy, with no Western price anchor to reference, launched in China below the category floor it inherits from. The next datapoint to watch is whether the reimbursement negotiation pulls the effective price — for domestic patients at least — into six figures. Nothing here is treatment advice.